Tech Company Financing Transactions
Mavupharma Funding Round
On 11/30/2017, Mavupharma raised $20 million in Series A funding from Frazier Healthcare Partners and Alpine BioVentures.
Transaction Overview
Company Name
Announced On
11/30/2017
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors
Frazier Healthcare Partners (Lead Investor) (Jamie Topper)
Proceeds Purpose
The Series A funding will be used primarily to advance Mavu's lead drug candidates into the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5400 Carillon Pt. Bldg. 5000 4th Floor
Kirkland, WA 98003
USA
Kirkland, WA 98003
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Operating Officer
Clayton Knox
Chief Scientific Officer
Greg Dietsch
President
Michael Gallatin
Browse more venture capital transactions:
Prev: 11/30/2017: Thrive Global venture capital transaction
Next: 12/1/2017: resTORbio venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs